Topical CBD and mitragynine nanoemulsion for neuropathic pain relief
SRIN Therapeutics presents a topical nanoemulsion combining nano-CBD and mitragynine for OTC relief of neuropathic pain. This non-opioid formulation enhances skin absorption and bioavailability, offering a clean, consumer-friendly solution.
Overview
SRIN Therapeutics introduces an innovative over-the-counter (OTC) topical nanoemulsion that combines nano-CBD (SRIN-009) and mitragynine, the active compound in kratom, to provide effective relief for neuropathic pain. This dual-action formulation is designed to target both peripheral and central mechanisms of pain, offering a non-opioid, science-backed alternative for consumers seeking relief. By employing a nanoemulsion delivery system, the product significantly enhances skin absorption and bioavailability, ensuring effective delivery of the active ingredients with minimal components for a clean formulation.
Technical specifications
- Active Ingredients: Nano-CBD (SRIN-009) and mitragynine
- Mechanism: Targets both peripheral and central neuropathic pain pathways
- Delivery System: Nanoemulsion for enhanced absorption and bioavailability
- Formulation: Oil-in-water nanoemulsion designed for topical application, available as a flexibly dosed liquid or patch
- Development Phase: Solubility studies to guide formulation, preclinical testing using CIPN rodent models
- Future Enhancements: Exploration of smart patches and adaptive delivery tools
Technology readiness level
Currently, the technology is at TRL 4, indicating that the product has been validated in the lab with strong preclinical data supporting its efficacy. SRIN Therapeutics plans further optimization and early user testing to advance its readiness for market launch.
About SRIN Therapeutics Inc.
SRIN Therapeutics Inc. is a Philadelphia-based pharmaceutical company founded in 2018 that focuses on developing novel treatments by harnessing the endocannabinoid system. The company is engaged in pharmaceutical manufacturing and research, specifically working on cannabinoid-based drug candidates intended to address various medical conditions, including cancer, autism, and post-traumatic stress disorder. Their therapeutic approach aims to mitigate the side effects of chemotherapy and provide cost-effective treatment alternatives. The company has pursued intellectual property protection for its developments, including patent applications related to cannabinoid compositions for immune modulation.
The company's mission is to fulfill unmet medical needs for patients globally by leveraging innovative therapeutic solutions. By focusing on the endocannabinoid system, SRIN Therapeutics seeks to offer safer or more accessible alternatives to traditional treatments such as opioid-based pain medications. The organization is led by founder and CEO Akhil Alugupalli and operates with a small, specialized team. The company remains in the development and research phase, with activities that have included the initiation of clinical trials and the pursuit of regulatory pathways for its pipeline drugs.
delivered to your inbox.